Vanda Pharmaceuticals Stock Rallies on FDA Filing
I'm PortAI, I can summarize articles.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares rose 2.2% to $7.06 after filing a Biologics License Application with the FDA for isidolimab, a treatment for pustular psoriasis. The stock hit a two-year high of $7.25, having risen over 47% this year. Short interest is 8.5% of the float, with increased bearish bets. Options activity shows 2,267 calls, double the average volume, with the January 16, 2026 8-strike call being most popular.
Source: Schaeffers The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments